Invention Grant
- Patent Title: Tetravalent dengue vaccine
-
Application No.: US17077206Application Date: 2020-10-22
-
Publication No.: US11945842B2Publication Date: 2024-04-02
- Inventor: Navin Khanna , Viswanathan Ramasamy
- Applicant: International Centre for Genetic Engineering and Biotechnology
- Applicant Address: IN New Delhi
- Assignee: INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY
- Current Assignee: INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY
- Current Assignee Address: IN New Delhi
- Agency: McDonnell Boehnen Hulbert & Berghoff LLP
- Priority: IN 78DEL2014 2014.09.01
- Main IPC: C07K14/005
- IPC: C07K14/005 ; A61K39/00 ; A61K39/12 ; A61K39/295 ; C12N7/00
Abstract:
The invention provides a recombinant polypeptide comprising the EDIII domain of each of Dengue virus serotype DENV-1, DENV-2, DENV-3, and DENV-4 linked to the N-terminal of HBsAg.
Public/Granted literature
- US20210122787A1 TETRAVALENT DENGUE VACCINE Public/Granted day:2021-04-29
Information query
